Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria
- PMID: 16890498
- DOI: 10.1016/j.meegid.2006.07.001
Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria
Abstract
Treatment efficacy is related to the interaction of three parameters: drug, parasites, and human factors. The role of human factors in treatment outcome has been poorly documented to date, although human genetic factors and specific immunity have been related to protection against malaria. This study aimed to evaluate a possible cooperation between drug efficacy and host factors in treatment success. The contribution of host factors to treatment efficacy was studied in Gabonese children with a non-severe malaria attack. Children (n=232) aged under 10 years were treated with either sulfadoxine-pyrimethamine or amodiaquine. The influence of erythrocyte-related genetic factors and humoral immune responses (IgG and subclasses) against MSP1(19) on anti-malarial treatment outcome during a 28-day follow-up was studied. Sickle-cell trait carriage and anti-MSP1(19) IgG3 levels were related to lower parasite densities at enrolment (multiple linear regression analysis, P<or=0.005). Strikingly, early failures after AQ or SP treatment were associated with decreased anti-MSP1(19) IgG, IgG1 and IgG3 levels at enrolment. However, this finding was achieved in a low number of children presenting with an early failure. Kinetics of anti-MSP1(19) IgG and subclasses between Days 0 and 28 were also related to treatment efficacy, as the most effective treatment (sulfadoxine-pyrimethamine) was characterised by a higher elevation of antibody titres by Day 28. No effect of erythrocyte-related genetic factors on treatment outcome was shown, although the protective role of sickle-cell trait against higher parasitaemias was confirmed at enrolment. Our data suggest that anti-MSP1(19) IgG1 may have a supportive role during the first days of treatment to prevent early failures. The interference between drug efficacy, immunity and human genetic factors needs further investigation to be elucidated.
Similar articles
-
Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria.J Infect Dis. 2003 Apr 1;187(7):1137-41. doi: 10.1086/368414. Epub 2003 Mar 13. J Infect Dis. 2003. PMID: 12660928 Clinical Trial.
-
Distribution of IgG subclass antibodies specific for Plasmodium falciparum glutamate-rich-protein molecule in sickle cell trait children with asymptomatic infections.Exp Parasitol. 2006 Feb;112(2):92-8. doi: 10.1016/j.exppara.2005.09.014. Epub 2005 Dec 13. Exp Parasitol. 2006. PMID: 16356497
-
Improved efficacy with amodiaquine instead of chloroquine in sulfadoxine/pyrimethamine combination treatment of falciparum malaria in Uganda: experience with fixed-dose formulation.Acta Trop. 2006 Nov;100(1-2):142-50. doi: 10.1016/j.actatropica.2006.10.007. Epub 2006 Nov 20. Acta Trop. 2006. PMID: 17113554 Clinical Trial.
-
Clinical and parasitological studies on immunity to Plasmodium falciparum malaria in children.Scand J Infect Dis Suppl. 1996;102:1-53. Scand J Infect Dis Suppl. 1996. PMID: 9060051 Review.
-
Innate immunity to malaria caused by Plasmodium falciparum.Clin Invest Med. 2002 Dec;25(6):262-72. Clin Invest Med. 2002. PMID: 12516999 Review.
Cited by
-
Associations between antibodies to a panel of Plasmodium falciparum specific antigens and response to sub-optimal antimalarial therapy in Kampala, Uganda.PLoS One. 2012;7(12):e52571. doi: 10.1371/journal.pone.0052571. Epub 2012 Dec 19. PLoS One. 2012. PMID: 23285095 Free PMC article. Clinical Trial.
-
Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes are associated with protection from treatment failure and the development of anemia in pregnancy.J Infect Dis. 2009 Jul 15;200(2):299-306. doi: 10.1086/599841. J Infect Dis. 2009. PMID: 19500037 Free PMC article. Clinical Trial.
-
Immunity as a predictor of anti-malarial treatment failure: a systematic review.Malar J. 2017 Apr 20;16(1):158. doi: 10.1186/s12936-017-1815-y. Malar J. 2017. PMID: 28427418 Free PMC article.
-
Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum.Malar J. 2007 Nov 16;6:153. doi: 10.1186/1475-2875-6-153. Malar J. 2007. PMID: 18021388 Free PMC article.
-
Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children.Malar J. 2008 Jul 29;7:142. doi: 10.1186/1475-2875-7-142. Malar J. 2008. PMID: 18664257 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources